Specialty Pharmacy

The treatment proved efficacy across all 3 key markers of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Tildrakizumab 100 mg shows significant efficacy in treating psoriatic arthritis, achieving key clinical trial end points and offering hope for patients.

Hospitals and health systems are adapting specialty and infusion pharmacy strategies to meet evolving payer mandates, rising costs, and shifting care models by expanding biosimilar use, optimizing prior authorizations, and integrating technology to enhance patient access and operational efficiency.

A phase 2 trial shows oxylanthanum carbonate (OLC) effectively manages hyperphosphatemia in patients with chronic kidney disease (CKD), offering a promising treatment option.

Sepiapterin treatment allowed patients to liberalize their diet while reaching or exceeding recommended daily protein allowances in patients living with phenylketonuria.

Independent specialty pharmacies face growing financial and operational pressures from rising drug costs, restrictive PBM contracts, and regulatory complexity, prompting many to explore strategic partnerships or sales as a means to sustain clinical excellence, preserve autonomy, and ensure long-term viability in an increasingly challenging health care environment.

Namrata Shah, MD, discusses the groundbreaking efficacy and patient-centered potential of twice-yearly lenacapavir for HIV preexposure prophylaxis (PrEP), supported by pivotal data from the PURPOSE trials.

The decentralization of US health care, accelerated by virtual care adoption, shifting reimbursement models, and a growing demand for complex therapies, is elevating the role of specialty and infusion pharmacies as essential, tech-enabled partners in delivering coordinated, patient-centered care across outpatient and home-based settings.

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).

A human-first support model helped boost adherence and outcomes, proving emotional connection is key to specialty medication success.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

Challenges faced by individuals living with HIV include weight gain, cardiovascular risks, and healthy aging strategies.

New research shows effective interventions can reduce prescriptions across all ages.

Experts discussed the promising future of pericarditis treatment.

The new formulation contains little IgA, reducing possible risks associated with infusion in patients with primary immunodeficiency.

Sebetralstat becomes the first FDA-approved oral treatment for hereditary angioedema (HAE), offering rapid relief for patients experiencing acute attacks.

Prescription digital therapeutics (PDTs) offer scalable, accessible alternatives to traditional treatments—supporting patients, providers, and payers while addressing gaps in mental health care.

Real-world data show that patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.

Expert explores the expanding role of FDA-approved Prescription Digital Therapeutics (PDTs).

The letter cited deficiencies previously identified at a third-party manufacturing vendor unrelated to oxylanthanum carbonate (OLC).

The injection is indicated for the treatment of sepsis and other serious infections, enhancing treatment efficiency and patient care.

Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.

The FDA approves emapalumab-lzsg as the first treatment for macrophage activation syndrome in Still disease, offering a new treatment approach for patients with the rare condition.

Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with a reduced incidence of cancer over time, although more research is necessary.

Explore the latest FDA-approved novel drugs transforming treatment options for various conditions, enhancing patient care and outcomes in community and specialty pharmacy.

In March, Utah became the first state to completely ban fluoridation.

Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.

The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition.